Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat Media Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostSubmitted by Chris Markoch. Publication Date: 2/5/2026. 
Key Takeaways - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped lift the Dow Jones Industrial Average (DJIA) after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion. On the bottom line, Pfizer delivered adjusted earnings per share (EPS) of $0.69, beating estimates of $0.57. Highlighting the report was Pfizer's announcement of positive topline results from the Phase 2b study for its lead GLP-1 candidate. The biggest tech investors have unloaded their top AI investments. Peter Thiel's fund dumped its entire $100 million Nvidia stake. SoftBank unloaded its entire $5.8 billion position. Perhaps the biggest signal is Berkshire Hathaway sitting on $382 billion in cash, more than Amazon, Microsoft, and Apple combined. Was this Warren Buffett's parting gift before stepping down? Four unstoppable market forces could upend the economy in the coming weeks. Any one could be devastating alone, but four at the same time would wreak havoc. The last time this played out was over 50 years ago, leading to a lost decade for stocks. Watch the interview revealing these four market forces. PFE stock closed up 4% on Feb. 4 as analysts and investors digested the report. The bullish thesis is that while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside is likely to come from its expanding oncology pipeline and accelerating use of artificial intelligence across R&D. That story begins with the company's push into obesity, where it reported a notable clinical update alongside the quarter. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is expanding rapidly. Data show the global GLP-1 market will grow from $62.2 billion in 2025 to $157 billion by 2035. That's a compound annual growth rate (CAGR) of about 9.7%, which helps explain why billions of dollars are flowing into the industry as companies compete for market share. For Pfizer, that opportunity centers on its lead GLP-1 candidate, MET-097i. The company announced results from its Phase 2b VESPER-3 study. The trial met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also highlighted that patients continued to lose weight after transitioning from weekly to monthly dosing, with no plateau observed by week 28. The Growth Driver Investors May Be Missing Immediately after the report, conventional wisdom attributed the stock's gain to the positive clinical trial results. That may be true, but it's worth noting that this kind of reaction can be a short-term "sugar high." While Pfizer's GLP-1 program shows promise, it will take time for those results to meaningfully impact the company's financials. And the GLP-1 trade itself is broadening — as Eli Lilly & Co. (NYSE: LLY) demonstrated, major pharma players are unlikely to cede leadership in obesity drugs anytime soon. However, there are other reasons to be bullish on PFE — notably its oncology portfolio. Data from Business Research Insights values the global oncology drugs market at roughly $264.92 billion in 2026, projected to grow to $648.08 billion by 2035, a CAGR of about 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer had roughly 60 candidates in its product portfolio — a large number of potential opportunities to capture market share. The portfolio was significantly strengthened by its acquisition of Seagen in 2023. Today, Pfizer's pipeline mixes late-stage candidates such as vepdegestrant, a next-generation targeted protein degrader (PROTAC), and atirmociclib, a selective CDK4 inhibitor, which are being evaluated in later-stage trials for ER+/HER2- metastatic breast cancer. Pfizer also has other late-stage candidates, including: - Sigvotatug vedotin, an antibody-drug conjugate (ADC) in Phase 3 testing (e.g., Be6A LUNG-01) for metastatic non-small-cell lung cancer, drawing on Seagen's ADC expertise.
- Sasanlimab, a candidate for bladder cancer, and a bispecific PD-1xVEGF agent (PF-4404) being tested in combination with Padcev for urothelial cancer — positioning these approaches for potential blockbuster status as oncology demand grows.
Over the next five to 10 years, Pfizer could bring multiple oncology drugs to market. That outlook is enhanced by the company's growing commitment to artificial intelligence (AI), which is rapidly becoming a core tool across the biopharmaceutical sector. Pfizer integrates AI across R&D through partnerships with firms such as Boltz for biomolecular modeling, XtalPi for molecular design, and Data4Cure for oncology data analytics, helping to accelerate target identification. Internal platforms like "Charlie" handle data mining, predictions, and content generation, while collaborations with NVIDIA (NASDAQ: NVDA) optimize discovery and manufacturing. These AI-enabled efforts were important in the company's rapid development of Paxlovid and support 2026 catalysts in oncology and obesity. Pfizer is targeting $1.2 billion in savings by 2027 from efficiency gains tied to AI and digital tools. Industry-wide, AI is projected to boost productivity by 35% to 45% by improving preclinical decision-making and trial design, making it a meaningful competitive advantage rather than mere hype. Pfizer's early and broad adoption of these tools should be a meaningful tailwind for investors over the medium to long term.
| 
